Recommendation of the President – Oxervate (cenegermin)

On 20 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 148/2024 on the appropriateness of granting approval for reimbursement of the drug Oxervate (cenegermin) for the indication: neurotrophic keratitis in adults

Publication in Public Information Bulletin (BIP) >>